Cue Biopharma Market Cap ($26.56 Million)
Market Cap & Net Worth: Cue Biopharma (CUE)
Cue Biopharma market cap. Cue Biopharma (NASDAQ:CUE) has a market capitalization of $26.56 Million ($26.56 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23996 globally and #5198 in its home market, demonstrating a 13.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cue Biopharma's stock price $20.86 by its total outstanding shares 91237736 (91.24 Million). Also see cash efficiency ratio of Cue Biopharma for how efficiently the company converts equity into cash flow.
Cue Biopharma Market Cap History (2018–2026)
Cue Biopharma market cap history from 2018 to 2026. Data shows growth from $428.82 Million to $1.90 Billion (6.83% CAGR). Check CUE stock price and chart for real-time trading data and today's change.
Index Memberships
Cue Biopharma is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #676 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2239 of 3165 |
Weight: Cue Biopharma's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cue Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cue Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Cue Biopharma annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
10.71x
Cue Biopharma's market cap is 10.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $428.82 Million | $1.14 Million | -$38.98 Million | 375.30x | N/A |
| 2019 | $1.45 Billion | $3.46 Million | -$36.70 Million | 418.85x | N/A |
| 2020 | $1.14 Billion | $3.15 Million | -$44.78 Million | 361.85x | N/A |
| 2021 | $1.03 Billion | $14.94 Million | -$44.16 Million | 69.06x | N/A |
| 2022 | $260.03 Million | $1.25 Million | -$53.01 Million | 208.86x | N/A |
| 2023 | $240.87 Million | $5.49 Million | -$50.73 Million | 43.87x | N/A |
| 2024 | $99.45 Million | $9.29 Million | -$40.67 Million | 10.71x | N/A |
Competitor Companies of CUE by Market Capitalization
Companies near Cue Biopharma in the global market cap rankings as of November 4, 2026. Also see CUE total assets for a full breakdown of the balance sheet.
Key companies related to Cue Biopharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Cue Biopharma (2018–2026)
Market capitalization of Cue Biopharma from 2018 to today. Between 2018 and today, Cue Biopharma's market cap moved from $428.82 Million to $ 1.90 Billion, with a yearly change of 6.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.90 Billion | +6730.39% |
| 2025 | $27.86 Million | -71.98% |
| 2024 | $99.45 Million | -58.71% |
| 2023 | $240.87 Million | -7.37% |
| 2022 | $260.03 Million | -74.80% |
| 2021 | $1.03 Billion | -9.59% |
| 2020 | $1.14 Billion | -21.20% |
| 2019 | $1.45 Billion | +237.77% |
| 2018 | $428.82 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Cue Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.56 Million USD |
| MoneyControl | $26.56 Million USD |
| MarketWatch | $26.56 Million USD |
| marketcap.company | $26.56 Million USD |
| Reuters | $26.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more